Principia Biopharma Announces Positive Data from Phase 2 Pemphigus Vulgaris Trial at 2019 American Academy of Dermatology Annual Meeting in Late-Breaking Presentation

NEXT STORY
Verrica Pharmaceuticals Presents Positive Results from Two Phase 3 Clinical Trials of VP-102 in Late-Breaking Oral Presentation at the 2019 American Academy of Dermatology Meeting
PREV STORY
Microbot Medical Maintains 2019 Milestone Targets Following Recent Court Decision
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

EyeGate Pharma Announces Positive Top-line Data from First-in-Human Pilot Trial of Ocular Bandage Gel in Corneal Epithelial Defects

WALTHAM, Mass., Jan. 30, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or ...

author_avatar
NASDAQ Market News

New Preclinical Study to Investigate the High Potency of Cymerus™ MSCs

author_avatar
NASDAQ Market News

BeyondSpring Enrolls First U.S. Patient in Phase 2/3 Clinical Trial of Plinabulin for Neutropenia Prevention

NEW YORK, April 25, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical ...

author_avatar
NASDAQ Market News